By CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.
Regeneron developing antibodies to target omicron as current cocktail loses potency against variant
Get the daily email that makes reading the news actually enjoyable.
Please Enter Your Email Address:
By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!
Comments